Results 191 to 200 of about 589,499 (392)

Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis

Movement Disorders, EarlyView.
Abstract Background Antidopaminergic medications (ADM) are often used for symptom management of Huntington's disease (HD). Evidence from past research suggests that ADMs are associated with worse clinical outcomes in HD, but their impact on various domains remains underexplored.
Michal Geva, Y. Paul Goldberg, Henk Schuring, Andrew M. Tan, Jeffrey D. Long, Michael R. Hayden   +5 more
wiley   +1 more source

Long‐Term Stability of Spatial Distribution and Peak Dynamics of Subthalamic Beta Power in Parkinson's Disease Patients

Movement Disorders, EarlyView.
Abstract Background Subthalamic beta oscillations are a biomarker for bradykinesia and rigidity in Parkinson's disease (PD), incorporated as a feedback signal in adaptive deep brain stimulation with potential for guiding electrode contact selection.
Jennifer K. Behnke, Robert L. Peach, Jeroen G.V. Habets, Johannes L. Busch, Jonathan Kaplan, Jan Roediger, Varvara Mathiopoulou, Lucia K. Feldmann, Moritz Gerster, Juliette Vivien, Gerd‐Helge Schneider, Katharina Faust, Patricia Krause, Andrea A. Kühn   +13 more
wiley   +1 more source

Ropinirole: A dopamine agonist for the treatment of Parkinson’s disease [PDF]

, 1999
Mary D. Kuzel
openalex   +1 more source

NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy

Movement Disorders, EarlyView.
Abstract Background Levodopa‐induced dyskinesia (LID) in Parkinson's disease (PD) is associated with ‘false neurotransmitter’ release of dopamine from serotonin (5‐HT) neurons. NLX‐112 is a first‐in‐class, highly selective 5‐HT1A receptor agonist which counteracts LIDs in experimental PD models.
Per Svenningsson, Per Odin, Filip Bergquist, Karin Wirdefeldt, Dag Nyholm, Mattias Andréasson, Ioanna Markaki, Anders C. Johansson, Måns Jergil, Christopher Jankosky, Mark A. Varney, Fabienne Herbrecht, Steven A. Johnson, Adrian Newman‐Tancredi   +13 more
wiley   +1 more source

Expanding the spectrum of KCNJ6‐related disorders: Milder phenotype with pathological startle responses

Clinical Genetics, Volume 103, Issue 1, Page 103-108, January 2023., 2023
We describe here the case of a 36‐year‐old female with a de novo pathogenic variant in KCNJ6 (NM_002240.5: c.460G>T; p.(Gly154Cys)) presenting with mild intellectual disability, subtle dysmorphic features, obsessive–compulsive disorder, and an exaggerated startle response, thereby expanding the spectrum of KCNJ6‐related disorders to milder phenotypes ...
Vesna Marija van Midden, Lisa Kinsley, Avram Fraint, Dimitri Krainc, Niccolò E. Mencacci   +4 more
wiley   +1 more source

The role of the neuromodulator adenosine in alcohols actions. [PDF]

, 1997
The interaction between the neuromodulator adenosine and adenosine receptors on the surface of neurons modifies the neurons responses to neurotransmitters.
Diamond, Ivan, Dohrman, D, Gordon, A
core  

Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine

, 1988
E. Ciccarelli, R. Touzel, Michael Besser, A. Grossman   +3 more
openalex   +1 more source

The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D_4.4 receptor [PDF]

, 1998
Lucien Gazi, Ionel Bobirnac, M Danzeisen, E. Schüpbach, Anne T. Bruinvels, Sabine Geisse, Bernd Sommer, Daniël Hoyer, Mark D. Tricklebank, Philippe Schoeffter   +9 more
openalex   +1 more source

Anosmia and Upper Limb Rigidity—A Potential Phenotype of Idiopathic Normal Pressure Hydrocephalus with Cerebrospinal Fluid α‐Synuclein Seeds

Movement Disorders, EarlyView.
Abstract Background The pathophysiology of idiopathic normal pressure hydrocephalus (iNPH) and its association with neurodegenerative disorders is poorly understood. Objectives The aim was to determine the prevalence of α‐synuclein pathology in iNPH and its associations with clinical characteristics. Methods We used α‐synuclein seed amplification assay
Sandrina Weber, Carly M. Farris, Yihua Ma, Mohammed Dakna, Maritta Starke, Sebastian Schade, Michael Bartl, Claudia Trenkwalder, Luis Concha‐Marambio, Brit Mollenhauer   +9 more
wiley   +1 more source

Biotransformation of l‐DOPA to Dopamine in the Substantia Nigra of Freely Moving Rats: Effect of Dopamine Receptor Agonists and Antagonists [PDF]

, 1998
Sophie Sarre, Diederik Vandeneede, Guy Ebinger, Yvette Michotte   +3 more
openalex   +1 more source